Application of the reversible proteasome inhibitor bortezomib to solid tumors is hindered by the need for frequent dosing, development of peripheral neuropathy (PN), and drug resistance. Carfilzomib, a second in class proteasome inhibitor, is a highly selective, irreversible inhibitor of the chymotrypsin-like activity of the proteasome, and is associated with reduced PN. The derivative compound, ONX 0912, offers a further advantage of being orally bioavailable.
Introduction
The proteasome plays an important role in regulating cell growth by promoting ubiquitin-mediated degradation of proteins that regulate cellular proliferation and survival (1) . Pharmacologic inhibition of the proteasome is emerging as a promising anti-cancer strategy. The 26S constitutive proteasome complex expressed in most cell types contains a 20S catalytic core with chymotrypsin-like (CT-L), caspase-like (C-L), and trypsin-like (T-L) activities (2, 3) . In vitro and in vivo studies have shown that the CT-L activity is rate limiting for proteolysis by the proteasome (3) (4) (5) . Bortezomib is a first-in-class compound that reversibly inhibits both the CT-L and C-L activities of the proteasome, and has been approved by the FDA for use in multiple myeloma and mantle cell lymphoma (6) (7) (8) (9) . Clinical application of bortezomib is limited by de novo and acquired resistance, as well as adverse toxicities (7, 8, (10) (11) (12) (13) . Development of peripheral neuropathy has been estimated at 35-52% in bortezomib-treated myeloma patients (10, 12, 14, 15) , with recent studies suggesting this may be due to off-target inhibition of cellular serine proteases, including cathepsins A and G, chymase, dipeptidyl peptidase II, and HtrA2/Omi (16) .
Carfilzomib, a next-generation irreversible proteasome inhibitor, is a tetrapeptide epoxyketone compound that displays a high degree of selectivity for the CT-L activity of the proteasome (17, 18) . Carfilzomib is well-tolerated in both mice and humans (18, 19) , and displays antitumor activity against lymphoma, myeloma, and Waldenstrom's Macroglobulinemia (17, 18, 20) . Notably, carfilzomib demonstrates activity against myeloma cells resistant to bortezomib, melphalan, and dexamethasone (17) . Synergism of carfilzomib with dexamethasone or histone deacetylase inhibitors has been reported (17, 21) . In contrast to bortezomib, carfilzomib fails to inhibit the C-L activity of the proteasome, or other serine protease targets of bortezomib (16) . The greater selectivity of carfilzomib may explain the low rates of peripheral neuropathy observed in early phase clinical trials with this agent .
Bortezomib and carfilzomib require intravenous or subcutaneous administration.
By contrast, ONX 0912, a recently generated derivative of carfilzomib, is orally 
Materials and Methods

Cells and Reagents
The human HNSCC cell lines UMSCC-22A, UMSCC-22B, 1483, UMSCC-1, and Cal33 (32) were grown at 37 o C in DMEM containing 10% heat-inactivated FBS (HyClone Laboratories), 100 units/mL penicillin, and 100 μg/mL streptomycin (Invitrogen). UMSCC-22A cells stably expressing GFP-LC3 (33) were maintained in medium containing 500 μg/mL G418 (Mediatech). All cell lines were genotypically validated using the AmpFlSTR® Profiler Plus™ kit from PE Biosystems, according to the manufacturer's instructions. E64d, pepstatin A, leupeptin, and chloroquine were from Sigma. 
Cell viability and apoptosis assays
Statistical analysis
For in vitro studies, the statistical significance of differences between two groups was determined by one-way ANOVA. For in vivo studies, two-way comparisons between tumor volumes of mice treated with vehicle or ONX 0912 were carried out using the Kruskal-Wallis exact test for K-independent samples with StatXact-9 (Cytel Studio, Cambridge MA) software. P values less than 0.05 were considered statistically significant.
Results
Carfilzomib and ONX 0912 induce apoptosis signaling and cell death in HNSCC cells
To investigate the activities of carfilzomib and ONX 0912 against HNSCC, we employed eight different cell lines ( Table 1 ). The HNSCC cells were treated for 48 hours with varying concentrations of carfilzomib or ONX 0912, followed by performance of trypan blue exclusion assays. The IC 50 values presented in Table 1 To confirm the induction of autophagy by carfilzomib and ONX 0912, we examined their effects on autophagasome formation (Fig. 3C) . UMSCC-22A cells stably expressing GFP-LC3 were treated with carfilzomib and ONX 0912, followed by fluorescence visualization of GFP-LC3-II localization to punctate cytoplasmic dots, an indicator of autophagasome formation (34). Treatment with carfilzomib and ONX 0912 led to a roughly 10-fold increase in the average number of puncta/cell, supporting the conclusion of autophagy induction.
Research. Autophagy induction by bortezomib has been shown to promote either cell death or cell survival, depending on the cell type studied (35-39). To determine whether the autophagy induction we observed serves a prodeath or a prosurvival role in HNSCC, cells were treated with carfilzomib in the absence or presence of the autophagy inhibitor chloroquine, followed by performance of trypan blue exclusion assays (Fig. 3D ).
Treatment with a subtoxic dose of chloroquine enhanced cell killing by carfilzomib in all 4 HNSCC cell lines examined. A similar trend, but reduced magnitude of effect was seen in ONX 0912-treated cells that were co-treated with chloroquine (Supplemental To determine whether ATF4 upregulation plays a role in carfilzomib-and ONX 0912-induced autophagy, we first performed a timecourse analysis of ATF4 and LC3-II expression (Fig. 4B) . ATF4 upregulation was first detected at 3 hours in carfilzomibtreated UMSCC-22A cells, and at 6 hours in cells treated with ONX 0912, with peak expression occurring 6 or 12 hours after treatment. Upregulation of LC3-II occurred with slower kinetics, with peak levels observed 48 hours after initiation of treatment. To further assess the role of ATF4, we inhibited expression using siRNA (Fig. 4C) . 
ONX 0912 inhibits HNSCC tumor growth in vivo
Research. 
The antitumor activity of orally administered ONX 0912 was investigated using nude mice harboring HNSCC xenograft tumors. In initial studies we sought to determine the impact of ONX 0912 on CT-L activity in the HNSCC tumors. Since ONX 0912 is an irreversible proteasome inhibitor, repeated treatment would be expected to result in cumulative proteasome inhibition. Therefore, a single oral administration of vehicle or ONX 0912 (10 or 30 mg/kg) was given to tumor-bearing mice (3/group), followed by harvest of tumors or normal tissues one hour later (Fig. 5A) . In liver tissue, CT-L activity was inhibited by greater than 50% at both doses of ONX 0912, while in blood and heart greater than 50% inhibition was only achieved at the 30 mg/kg dose. In the HNSCC tumors, greater than 50% CT-L inhibition was seen at 30 mg/kg (although 
we observed dose-dependent antitumor effects of carfilzomib (consecutive-day/once per week, intravenous delivery of 3 or 5 mg/kg carfilzomib; Supplemental Fig. 7 ). 
DISCUSSION
peripheral neuropathy, is seen in bortezomib-treated patients. Recent studies indicate that these adverse events are due to off-target, nonproteasomal effects of bortezomib (16) . Bortezomib inhibits both the CT-L and C-L activities of the proteasome, and also inhibits the serine proteases chymase, dipeptidyl peptidase II, HtrA2/Omi, and cathepsins A and G. Inherent and acquired resistance to bortezomib represents a further limitation to treatment. 
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